Tiziana Life Sciences’ intranasal foralumab has cleared an important credibility hurdle with the peer-reviewed publication of its open-label study in non-active secondary progressive multiple sclerosis in Neurology Neuroimmunology & Neuroinflammation. In ten patients progressing despite prior B‑cell therapies, at least six months of nasal foralumab was associated with stabilization of disability scores for all participants, improvement in three of four treated for 12 months, reduced fatigue in the majority, no new T2 lesions on MRI, and statistically significant reductions in microglial activation on TSPO‑PET at three and six months. Single‑cell RNA sequencing pointed to sustained increases in regulatory T cells and TGFβ expression, aligning the clinical and imaging signals with a plausible immunomodulatory mechanism. A randomized, double‑blind, placebo‑controlled Phase 2 trial in non-active SPMS is ongoing, with top-line data expected in the first half of 2026.
The immediate strategic question is whether biomarker-rich, small-sample data can translate into payer-credible, regulator-accepted evidence of disability slowing in a notoriously unforgiving population. Non-active SPMS remains one of MS’s most intractable settings, where relapse-driven anti-inflammatory agents have limited impact on progression independent of relapse activity. If a nasal anti‑CD3 approach can modulate microglial-driven neuroinflammation without broad systemic immunosuppression, the therapeutic and commercial calculus could shift meaningfully for a population with few viable options.
For patients, the appeal is self-evident: a non‑infusional, potentially better‑tolerated therapy aimed at the biology of progression rather than relapses. For HCPs, the integration of TSPO‑PET, proteomics, and clinical measures offers a mechanistic throughline that is often missing in progressive MS programs. Yet adoption will hinge on unequivocal randomized data showing a clinically meaningful effect on confirmed disability progression over a relevant time horizon. For payers, the path to access will rely less on imaging or immune signatures than on hard outcomes—time to confirmed EDSS worsening, ambulation metrics, and persistence—augmented by quality‑of‑life gains such as fatigue reduction. TSPO‑PET could emerge as a response‑enrichment or pharmacodynamic tool, but standardization, cost, and availability will limit its use beyond trials unless it directly correlates with outcomes.
Commercially, a nasal anti‑CD3 that demonstrates disease modification in non‑active SPMS would occupy a largely uncontested niche, with potential to extend into earlier progressive phenotypes or combination strategies. The route of administration could favor specialty pharmacy distribution and patient convenience, while a safety profile that avoids broad immunosuppression would differentiate against chronic infusion backbones. However, the open‑label origin of the dataset, the small sample size, and the need to replicate benefit in a blinded setting temper near‑term expectations and will shape payer negotiations and HCP education plans.
The broader industry context is compelling. Multiple programs, notably BTK inhibitors, are pursuing microglial and compartmentalized CNS inflammation as the next frontier in MS, but safety, consistency, and regulatory paths remain unsettled. Tiziana’s approach adds a different lever—mucosal tolerance via anti‑CD3—backed by convergent biomarker evidence. In a capital‑scarce environment, peer‑reviewed validation of a mechanistic signal can catalyze partnerships and non‑dilutive financing, but only if it is followed quickly by decisive randomized readouts and a clear biomarker‑to‑outcome story.
The next 18 months will determine whether foralumab’s biomarker alignment converts into a disability‑focused label trajectory. If the Phase 2 data confirm a clinically meaningful effect in non‑active SPMS, how rapidly can the program scale into a registrational design that marries pragmatic endpoints with biomarker‑driven enrichment—and will that be enough to set a new standard in progressive MS where others have struggled to move the needle?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
